June 3rd, 2014
Implantable cardioverter-defibrillators are routinely implanted in heart failure patients with ejection fractions of 35% and lower to prevent sudden cardiac death. However, the benefits in patients at the higher end of the spectrum — EFs between 30% and 35% — have not been well demonstrated in clinical trials, since few patients in this range have […]
May 8th, 2014
This week’s topics include darapladib for preventing ischemic events in stable CHD, the DAMASCENE analysis, a review of John Brush’s new book, and more.
April 9th, 2014
Although a significant portion of people with heart failure have preserved ejection fraction, none of the proven heart failure therapies has been shown to be beneficial in this important and growing heart failure subpopulation. Now a new NHLBI-funded study has failed to find a benefit in this group for spironolactone, which is a cornerstone of […]
February 4th, 2013
This week’s topics include blood transfusion and increased mortality in MI, proteotoxicity and cardiac dysfunction in the elderly, combined fitness and statin treatment on mortality in veterans with dyslipidemia, and more.
December 3rd, 2012
This week’s topics include the association between aldosterone-antagonist therapy and mortality and readmission among patients with HF and reduced EF, warfarin therapy after bioprosthetic AVR, and more.